title: The inhibitory effect of zoledronate on early-stage osteoinduction by recombinant human bone morphogenetic protein 2 in an osteoporosis model.
abstract: This study evaluated the effect of the combined treatment of intravenous zoledronic acid (ZA, 0.08 mg/kg) and rhBMP-2 (5 µg) on osteogenesis in a calvarial defect model of ovariectomized SD rats. New bone formation was evaluated 4 or 8 weeks after calvarial defect implantation using micro-CT and histology. Micro-CT results revealed that the rhBMP-2 group showed significantly higher calvarial defect coverage ratio compared with the ZA + rhBMP-2 group at 4 weeks. In addition, bone formation indices were significantly lower in ZA + rhBMP-2 group when compared with the rhBMP-2 group after 4 weeks, which indicates a negative effect of ZA on the initial bone formation and the bone quality. At 8 weeks, the negative effect induced by ZA treatment was alleviated as time passed. Histological examination showed similar results to the micro-CT measurements. In conclusion, although ZA treatment lowered the new bone formation induced by rhBMP-2 initially, as time passed, the negative effect was decreased.
authors.affiliation: a Department of Orthopedic Surgery , College of Medicine, Seoul National University, SMG-SNU Boramae Medical Center , Seoul , Republic of Korea and.|b Institute of Medical and Biological Engineering, Seoul National University Medical Research Center , Seoul , Republic of Korea.
authors.forename: Jae Hyup
authors.initials: JH
authors.lastname: Lee
authors.affiliation: a Department of Orthopedic Surgery , College of Medicine, Seoul National University, SMG-SNU Boramae Medical Center , Seoul , Republic of Korea and.
authors.forename: Hae-Ri
authors.initials: HR
authors.lastname: Baek
authors.affiliation: a Department of Orthopedic Surgery , College of Medicine, Seoul National University, SMG-SNU Boramae Medical Center , Seoul , Republic of Korea and.
authors.forename: Kyung Mee
authors.initials: KM
authors.lastname: Lee
authors.affiliation: a Department of Orthopedic Surgery , College of Medicine, Seoul National University, SMG-SNU Boramae Medical Center , Seoul , Republic of Korea and.
authors.forename: Guang Bin
authors.initials: GB
authors.lastname: Zheng
authors.affiliation: a Department of Orthopedic Surgery , College of Medicine, Seoul National University, SMG-SNU Boramae Medical Center , Seoul , Republic of Korea and.
authors.forename: Sung Joon
authors.initials: SJ
authors.lastname: Shin
authors.affiliation: a Department of Orthopedic Surgery , College of Medicine, Seoul National University, SMG-SNU Boramae Medical Center , Seoul , Republic of Korea and.
authors.forename: Yuan Zhe
authors.initials: YZ
authors.lastname: Jin
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D055396:Bone Morphogenetic Protein 2 / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects; D004164:Diphosphonates / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D010012:Osteogenesis / Q000187:drug effects*; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use; D012886:Skull / Q000378:metabolism* / Q000601:surgery; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects; D055114:X-Ray Microtomography; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D055396:Bone Morphogenetic Protein 2; D004164:Diphosphonates; D007093:Imidazoles; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D000077211:Zoledronic Acid
keywords: Bone morphogenetic protein-2; calvarial defect model; osteogenesis; zoledronic acid